Welcome to our dedicated page for CATALYST PHARMACEUTICALS SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Catalyst Pharmaceuticals files regulatory disclosures that document material events for its rare-disease biopharmaceutical business and Nasdaq-listed common stock. Recent Form 8-K and 8-K/A filings cover operating results and business updates, Regulation FD presentation materials, press-release exhibits, and capital-structure matters including a board-authorized share repurchase program.
The filings also record company-specific legal and intellectual property disclosures, including FIRDAPSE Orange Book patent litigation, amendments to prior material-event reports, and settlement-related corrections. These documents tie formal disclosures to Catalyst’s commercial products, governance actions, exhibit filings, and public-company reporting obligations.
Catalyst Pharmaceuticals completed its merger with Angelini Pharma on July 15, 2026, when Angelini subsidiary Angelini Cielo merged with and into Catalyst, which continues as a wholly owned subsidiary of Angelini Pharma.
At the effective time, each share of Catalyst common stock was converted into the right to receive $31.50 in cash per share, without interest and subject to tax withholding. Catalyst notified Nasdaq of the merger, requested delisting, and trading in its stock will be suspended on July 16, 2026, followed by deregistration and termination of SEC reporting obligations. All pre-merger directors resigned and Angelini designees joined the board, and the company’s certificate of incorporation and bylaws were amended and restated as provided in the Merger Agreement.
Catalyst Pharmaceuticals, Inc. has had its common stock designated for removal from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Exchange Act, through a Form 25 notification. Nasdaq states it has followed its rules to strike this class of securities, citing SEC Rule 12d2-2.
Catalyst Pharmaceuticals reported that its stockholders approved the planned merger with Angelini Pharma, under which Catalyst will become a wholly owned subsidiary of Angelini. The merger proposal received 97,340,180 votes for, 1,143,815 against and 242,616 abstentions, satisfying a key closing condition in the Merger Agreement.
At the special meeting, 98,726,611 shares, or about 80.6% of the 122,417,458 shares outstanding as of the record date, were represented. Stockholders did not approve, on a non-binding advisory basis, the merger-related executive compensation proposal, but this does not affect completion of the merger. All current directors have indicated they will resign at the effective time of the merger.
Catalyst Pharmaceuticals reported topline results from a two-part Phase 1 clinical study of AGAMREE (vamorolone) in healthy adult volunteers. The study showed balanced corticosteroid activity, with expected cortisol suppression and no evidence of significant immunosuppressive activity at clinical doses.
In Part A, vamorolone produced similar cortisol suppression to deflazacort at label-based clinical doses, supporting currently labeled dosing for Duchenne muscular dystrophy. In Part B, even at an ascending dose up to 40 mg/kg/day, which is above currently approved dosing, the data did not indicate clinically meaningful immunosuppression, reinforcing its potential use across a broad range of chronic inflammatory rare diseases.